Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG trial: low-dose rituximab maintenance in immune thrombocytopenia
2015-005276-14Phase 3Completed
- Sponsor
- Ostfold Hospital Trust
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in immune thrombocytopenia (ITP) (4 arms), sponsored by Ostfold Hospital Trust. Primary endpoint: Prolongation of response with low-dose rituximab maintenance. Started Feb 2016; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2015-005276-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005276-14.